Exelixis
EXEL
#1574
Rank
NZ$19.24 B
Marketcap
$68.76
Share price
2.76%
Change (1 day)
90.98%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

Earnings for Exelixis (EXEL)

Earnings in 2024 (TTM): NZ$1.13 Billion

According to Exelixis's latest financial reports the company's current earnings are NZ$2.16 Billion. , an increase over its 2023 earnings that were of NZ$0.45 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Exelixis from 2000 to 2024

Annual earnings

Year Earnings Change
2024 NZ$1.21 B164.69%
2023 NZ$0.45 B9.89%
2022 NZ$0.41 B-20.33%
2021 NZ$0.52 B124.82%
2020 NZ$0.23 B-67.14%
2019 NZ$0.70 B-11.94%
2018 NZ$0.80 B185.09%
2017 NZ$0.28 B-325.82%
2016 -NZ$0.13 Billion-58.12%
2015 -NZ$0.3 Billion-37.61%
2014 -NZ$0.48 Billion9.75%
2013 -NZ$0.44 Billion65.96%
2012 -NZ$0.27 Billion-291.63%
2011 NZ$0.13 B-195.59%
2010 -NZ$0.15 Billion-42.17%
2009 -NZ$0.25 Billion-18.98%
2008 -NZ$0.31 Billion-6.99%
2007 -NZ$0.33 Billion46.3%
2006 -NZ$0.23 Billion33.25%
2005 -NZ$0.17 Billion-30.92%
2004 -NZ$0.25 Billion44.29%
2003 -NZ$0.17 Billion12.86%
2002 -NZ$0.15 Billion22.79%
2001 -NZ$0.13 Billion60.14%
2000 -NZ$76.17 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
NZ$7.41 B 511.89%๐Ÿ‡ฌ๐Ÿ‡ง UK
NZ$14.11 B 1,065.14%๐Ÿ‡ซ๐Ÿ‡ท France
NZ$26.60 B 2,096.61%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$14.9 Billion-1,329.24%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$8.19 B 576.16%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$30.99 B 2,458.83%๐Ÿ‡บ๐Ÿ‡ธ USA
NZ$12.33 B 918.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$79.63 Million-106.57%๐Ÿ‡บ๐Ÿ‡ธ USA
-NZ$51.61 Million-104.26%๐Ÿ‡บ๐Ÿ‡ธ USA